GLMD
Galmed Pharmaceuticals Ltd
NASDAQ: GLMD · HEALTHCARE · BIOTECHNOLOGY
$0.58
-4.67% today
Updated 2026-06-05
Market cap
$4.59M
P/E ratio
—
P/S ratio
61.38x
EPS (TTM)
$-2.39
Dividend yield
—
52W range
$0 – $2
Volume
3.8M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.5
Quality
C+3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$12.00
+1967.54%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-1.95M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-17.87M | $-6.91M | $-7.52M | $-10.31M | $-4.82M |
| EPS | — | — | — | — | $-2.39 |
| Free cash flow | $-18.50M | $-6.14M | $-5.88M | $-6.32M | $-1.95M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Galmed Pharmaceuticals Ltd trades at $0.58. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score.
Frequently asked questions
What is Galmed Pharmaceuticals Ltd's stock price?
Galmed Pharmaceuticals Ltd (GLMD) trades at $0.58, on a P/S of 61.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Galmed Pharmaceuticals Ltd overvalued?
Galmed Pharmaceuticals Ltd carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Galmed Pharmaceuticals Ltd (GLMD)?
The 12-month analyst consensus target is $12.00, about 1967.5% above the current $0.58. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio61.38x
ROE-65.32%
Beta0.71
50D MA$0.63
200D MA$0.94
Shares out0.01B
Float0.01B
Short ratio—
Avg volume3.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—